SEARCH

SEARCH BY CITATION

References

  • 1
    Poynard T, Marcellin P, Lee S, Niederau C, Minuk G, Ideo G, et al. Randomised trial of interferon alpha 2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha 2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 1998; 352: 14261432.
  • 2
    McHutchison JG, Gorelick RJ, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Eng J Med 1998; 339: 14851492.
  • 3
    Marcellin P, Boyer N, Gervais A, Martinot M, Pouteau M, Castelnau C, et al. Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy. Ann Int Med 1997; 127: 875881.
  • 4
    Lau DT, Kleiner DE, Ghany MG, Park Y, Schmid P, Hoofnagle J. 10-year follow-up after interferon therapy for chronic hepatitis C. HEPATOLOGY 1998; 28: 11211127.
  • 5
    Reichard O, Glaumann H, Fryden A, Norkrans G, Wejstal R, Weiland O. Long-term follow-up of chronic hepatitis C patients with sustained virological response to alpha-interferon. J Hepatol 1999; 30: 783787.
  • 6
    Veldt BJ, Heathcote EJ, Wedemeyer H, Reichen J, Hofmann P, Zeusem S, et al. Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann Int Med 2007; 147: 677684.
  • 7
    Poynard T, McHutchinson JG, Manns M, Trepo C, Lindsay KL, Goodman Z, et al. Impact of pegylated interferon alpha 2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 2002; 122: 13031313.
  • 8
    Arthur MJP. Reversibility of liver fibrosis and cirrhosis following treatment for hepatitis C. Gastroenterology 2002; 122: 15251528.
  • 9
    Saracco G, Rosina F, Abate ML, Chiandussi L, Gallo V, Cerutti E, et al. Long-term follow-up of patients with chronic hepatitis C treated with different doses of interferon-alpha 2b. HEPATOLOGY 1993; 18: 13001305.
  • 10
    Tsubota A, Kumada H, Chayama K, Arase Y, Saitoh S, Koida I, et al. Time course of histological changes in patients with a sustained biochemical and virological response to interferon-α therapy for chronic hepatitis C virus infection. J Hepatol 2007; 27: 4955.
  • 11
    Camma C, Di Marco V, Lo Iacono O, Almasio P, Giunta M, Fuschi P, et al. Long-term course of interferon-treated chronic hepatitis C. J Hepatol 1998; 28: 531537.
  • 12
    Pradat P, Tillmann HL, Sauleda S, Braconnier J-H, Saracco G, Thursz M, et al. Long-term follow-up of the hepatitis C HENCORE cohort: response to therapy and occurrence of liver-related complications. J Viral Hepat 2007; 14: 556563.
  • 13
    Shiratori Y, Imazeki F, Moriyama M, Yano M, Arakawa Y, Yokosuka O, et al. Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy. Ann Int Med 2000; 132: 517524.
  • 14
    Veldt BJ, Saracco G, Boyer N, Camma C, Bellobuono A, Hopf U, et al. Long term clinical outcome of chronic hepatitis C patients with sustained virological response to interferon monotherapy. Gut 2004; 53: 15041508.
  • 15
    Brunt EM. Grading and staging the histopathological lesions of chronic hepatitis: the Knodell histology activity index and beyond. HEPATOLOGY 2000; 31: 241246.
  • 16
    Fanson B, Osmack P, Di Bisceglie AM. A comparison between the phenol-chloroform method of RNA extraction and the QIAamp viral RNA kit in the extraction of hepatitis C and GB virus-C/hepatitis G viral RNA from serum. J Virol Methods 2000; 89: 2327.
  • 17
    Gorrin G, Friesenhahn M, Lin P, Sanders M, Pollner R, Eguchi B, et al. Performance Evaluation of the VERSANT HCV RNA qualitative assay by using transcription-mediated amplification. J Clin Micro 2003; 41: 310317.
  • 18
    Toccaceli F, Laghi V, Capurso L, Koch M, Sereno S, Scuderi M. Long-term liver histology improvement in patients with chronic hepatitis C and sustained response to interferon. J Viral Hepat 2003; 10: 126133.
  • 19
    Akuta N, Suzuki F, Suzuki Y, Sezaki H, Hosaka T, Someya T, et al. Long-term follow-up of interferon monotherapy in 454 consecutive naive patients infected with hepatitis C virus: multi-course interferon therapy may reduce the risk of hepatocellular carcinoma and increase survival. Scand J Gastroenterol 2005; 40: 688696.
  • 20
    Imazeki F, Yokosuka O, Fukai K, Saisho H. Favorable prognosis of chronic hepatitis C after interferon therapy by long-term cohort study. HEPATOLOGY 2003; 38: 493502.
  • 21
    Ikeda M, Fujiyama S, Tanaka M, Sata M, Ide T, Yatsuhashi H, et al. Risk factors for development of hepatocellular carcinoma in patients with chronic hepatitis C after sustained response to interferon. J Gastroenterol 2005; 40: 148156.